04- PHARMA/BIOTECH

AI To Be Used To identify Chronic Diseases Earlier – Theresa Says

Really!!! Have they any idea of implications for NHS – can they cope with the rush for treatment <<<AI>>

Read More

Anticholinergics For Depression Increase Likelihood Of AD Onset

Fairly logical really but certainly a 40,000 patient study would give weight to the conclusions!!! Also adds weight to the use of AChEs for the symptomatic relief of cognitive symptoms in confirmed AD patients   <<<AntiCholinergics>>>

Read More

UK Life Science Industry Strategy

HoL picked up on basic deficiency in this strategy then Give it to the NHS but don’t tell them 🙂 <<<NHS>>>

Read More

Alzheimer’s Classification System

For too long AD have been a too highly variable environment for clinical research! -The patients present with highly variable conditions -The treatments have widely different modes of action and possible targets -The assessment measures are highly variable and subject to large errors No wonder it has been almost impossible to pick up any indicators […]

Read More

ApoE And Alzheimers

Subjects with 2 ApoE4 genes are 12 times more likely to get AD than those with the normal gene (ApoE3) So although scientists know that amyloid protein breakdown is important in the disease therapeutics targetting these proteins has been one long list of failures This is a very interesting potential explanation – neurons produced from […]

Read More

Another Failure In Alzheimer’s

First it was Lilly then Pfizer then Axovant then Merck and almost Biogen/Eisai and now vTV (whoever they are) But then it was only 2 lots of 400 patients and the ADAS and CDR – what did they expect! <<<ALZ>>>

Read More

Blockchain In Clinical Development

Very interesting stuff from Pharma Times Distributed security applied to patient health records right through to drug supply <<<BLOCKCHAIN>>>

Read More

NICE Ruling Combined Therapy For AD

I thought combined therapy was already approved Worth trying anything once the AD symptoms appear! Even though I’ve never been convinced about memantine <<<MEMANTINE>>>

Read More

High Placebo Response In Depression (MDO)

This article refers to the high placebo response rate (50%) in MDO specifically but equally appplies to all therapeutic areas >>> >>>GET RECRUITMENT RIGHT -True MDO patients -True assessment by clinicians to select right subjects (keen to influence score on in/ex) -Personnel lack of understanding of AIM = to test null hypothesis /estimate treatment effect […]

Read More

Investigator Payments

A large proportion (84%) of NHS hospitals apparently still don’t declare finances received from drug companies Isn’t this a violation of the ABPI code of practice? I don’t see what the problem is BOTH Investigators (and Patients!) should be paid for work performed in clinical development BUT it all should be in the open and […]

Read More